Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy
Author:
Affiliation:
1. Department of Urology, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference28 articles.
1. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder;Epstein;Am J Surg Pathol,1998
2. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors;Morales;J Urol,1976
3. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma;Brosman;J Urol,1982
4. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS);Smith;J Urol,1999
5. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2005
Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy;Urologic Oncology: Seminars and Original Investigations;2023-11
2. New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer;Bladder Cancer;2023-09-25
3. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets;International Journal of Molecular Sciences;2023-08-09
4. Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer;memo - Magazine of European Medical Oncology;2023-07-25
5. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE);European Urology Focus;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3